Advertisement
Canada markets closed
  • S&P/TSX

    22,167.03
    +59.95 (+0.27%)
     
  • S&P 500

    5,254.35
    +5.86 (+0.11%)
     
  • DOW

    39,807.37
    +47.29 (+0.12%)
     
  • CAD/USD

    0.7387
    +0.0001 (+0.01%)
     
  • CRUDE OIL

    83.11
    -0.06 (-0.07%)
     
  • Bitcoin CAD

    94,839.02
    -2,043.77 (-2.11%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • GOLD FUTURES

    2,254.80
    +16.40 (+0.73%)
     
  • RUSSELL 2000

    2,124.55
    +10.20 (+0.48%)
     
  • 10-Yr Bond

    4.2060
    +0.0100 (+0.24%)
     
  • NASDAQ

    16,379.46
    -20.06 (-0.12%)
     
  • VOLATILITY

    13.01
    0.00 (0.00%)
     
  • FTSE

    7,952.62
    +20.64 (+0.26%)
     
  • NIKKEI 225

    40,369.44
    +201.37 (+0.50%)
     
  • CAD/EUR

    0.6836
    -0.0007 (-0.10%)
     

S.Africa's Aspen signs non-binding agreement with J&J for COVID vaccine license

JOHANNESBURG, Nov 30 (Reuters) - South Africa's Aspen Pharmacare on Tuesday signed a non-binding agreement with subsidiary firms of U.S. company Johnson & Johnson as part of its negotiations for a licensing deal to package, market and sell the latter's COVID-19 vaccine in Africa, it said in a statement.

Aspen currently packages J&J's COVID-19 vaccine at its South African plant under contract, which means it does not have any pricing or distribution power over the product.

Aspen has signed a non-binding term sheet with two of the Janssen Pharmaceutical Companies of J&J that will form the basis for negotiation of a definitive agreement on the manufacture and sale of an Aspen branded COVID-19 vaccine throughout Africa. (Reporting by Promit Mukherjee, editing by Estelle Shirbon)